Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Lopez-Muñoz N, Bar N, Diels J, van Sanden S, Mendes J, Lee S, Hernando T, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Shah U. Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2024, 144: 3390. DOI: 10.1182/blood-2024-201568.Peer-Reviewed Original ResearchProgression-free survivalRelapsed/refractory multiple myelomaUnanchored matching-adjusted indirect comparisonMatching-adjusted indirect comparisonCilta-celIde-celCARTITUDE-1Overall survivalMultiple myelomaCAR-TIdecabtagene vicleucelIndirect comparisonsProteasome inhibitorsKaplan-MeierChimeric antigen receptor T cellsHazard ratioPresence of extramedullary diseaseAnti-CD38 monoclonal antibodyTreatment of adult patientsB-cell maturation antigenRisk of disease progressionConfidence intervalsTreatment of multiple myelomaRefractory to lenalidomideCAR-T treatment